Skip to main content

Table 6 Univariate and multivariate analysis of clinicopathologic factors for DFS

From: Adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy: a retrospective control study

Variables Univariate Multivariate
HR 95% CI P HR 95% CI P
Age (years)
 < 60 yr 1.000      
 ≥ 60 yr 1.297 0.955–1.760 0.096    0.301
Sex
 Male 1.000      
 Female 1.208 0.873–1.671 0.254    
BMI
 < 23 1.000      
 ≥ 23 0.970 0.714–1.318 0.847    
Surgical approach
 Traditional open 1.000      
 Laparoscopic-assisted 0.802 0.576–1.116 0.191    0.264
Intraoperative blood loss
 ≤ 100 ml 1.000    1.000   
 >100 ml 1.777 1.252–2.522 0.001 1.829 1.279–2.615 0.001
Postoperative complications
 Negative 1.000      
 Positive 1.365 0.892–2.090 0.151    0.838
Tumor length/diameter
 < 5 cm 1.000      
 ≥ 5 cm 1.929 1.421–2.619 < 0.001    0.053
Histological type
 HD/MD/M-LD 1.000      
 LD/MA/SRC 1.506 1.108–2.047 0.009    0.129
Vascular tumor embolus
 Negative 1.000      
 Positive 1.779 1.285–2.464 0.001    0.901
Depth of Invasion (T)
 T1/T2/T3 1.000      
 T4a/T4b 2.149 1.572–2.939 < 0.001    0.207
Lymph node metastasis (N)
 N0/N1 1.000      
 N2/N3 2.650 1.897–3.701 < 0.001    0.690
TNM    < 0.001    < 0.001
 IIA       
 IIB 2.748 1.380–5.469 0.004 2.634 1.323–5.246 0.006
 IIIA 3.216 1.715–6.033 < 0.001 3.347 1.783–6.281 < 0.001
 IIIB 6.268 3.340–11.762 < 0.001 6.941 3.687–13.065 < 0.001
 IIIC 12.823 6.476–25.392 < 0.001 13.420 6.751–26.677 < 0.001
Serum CEA level
 ≤ 5 ng/ml 1.000      
 >5 ng/ml 1.022 0.701–1.490 0.911    
Serum CA199 level
 ≤ 37 U/ml 1.000      
 >37 U/ml 1.291 1.057–1.578 0.012    0.840
Adjuvant chemotherapy cycles    0.002    < 0.001
 Not received (A) 1.000    1.000   
 7–8 or 10–12 cycles (B) 0.549 0.369–0.817 0.003 0.424 0.283–0.635 < 0.001
 4–6 or 6–9 cycles (C) 0.592 0.381–0.918 0.019 0.522 0.335–0.815 0.004
 ≤ 3 or 5 cycles (D) 1.058 0.664–1.687 0.812 0.836 0.519–1.349 0.464
  1. Note: HD/MD/M-LD High/Median/Median-Low differentiation adenocarcinoma, LD/MA/SRC Low differentiation adenocarcinoma/Mucinous adeno-carcinoma/ Signet-ring cell carcinoma, HR Hazard ratio, CI Confidence interval. P < 0.05, statistically significant